{"id":15934,"date":"2025-02-25T11:42:25","date_gmt":"2025-02-25T11:42:25","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?p=15934"},"modified":"2025-07-30T14:15:11","modified_gmt":"2025-07-30T14:15:11","slug":"laspirine-reduit-le-risque-de-recidive-du-cancer-colorectal-chez-les-patients-presentant-des-mutations-p13k","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/laspirine-reduit-le-risque-de-recidive-du-cancer-colorectal-chez-les-patients-presentant-des-mutations-p13k\/","title":{"rendered":"L&rsquo;aspirine r\u00e9duit le risque de r\u00e9cidive du cancer colorectal chez les patients pr\u00e9sentant des mutations P13K"},"content":{"rendered":"<p><strong>Mars 2025<\/strong><\/p>\n<p>Une \u00e9tude de phase 3 pr\u00e9sent\u00e9e lors du\u00a0<em>Gastrointestinal Cancers Symposium<\/em>\u00a0de 2025 a montr\u00e9 que l&rsquo;utilisation d&rsquo;aspirine pendant trois ans r\u00e9duisait de mani\u00e8re significative le risque de r\u00e9cidive chez les patients atteints de cancer colorectal pr\u00e9sentant des mutations du g\u00e8ne\u00a0<em>PIK3CA<\/em>.<\/p>\n<p><strong>Qu&rsquo;est-ce que\u00a0<em>PIK3CA<\/em>?<\/strong><\/p>\n<p><em>PIK3CA<\/em>\u00a0est un g\u00e8ne commun\u00e9ment mut\u00e9 (modifi\u00e9) dans de nombreux types de cancer et dans 10 \u00e0 20 % des cancers colorectaux. Une mutation du\u00a0<em>PIK3CA<\/em>\u00a0favorise la croissance des cellules.<\/p>\n<p><strong>L&rsquo;essai<\/strong><\/p>\n<p>L&rsquo;\u00e9tude ALASCCA a r\u00e9v\u00e9l\u00e9 une diminution de 51 % du risque de r\u00e9cidive chez les patients pr\u00e9sentant des sous-types de mutations\u00a0<em>PIK3CA<\/em>\u00a0(exon 9\/20) et une diminution de 58 % chez ceux pr\u00e9sentant des alt\u00e9rations PIK3R1\/PTEN\/autres\u00a0<em>PIK3CA<\/em>\u00a0apr\u00e8s trois ans d&rsquo;utilisation d&rsquo;aspirine. L&rsquo;\u00e9tude indique \u00e9galement que les avantages de l&rsquo;aspirine peuvent s&rsquo;\u00e9tendre au-del\u00e0 des mutations\u00a0<em>PIK3CA<\/em>\u00a0et b\u00e9n\u00e9ficier potentiellement \u00e0 40 % des patients atteints de cancer colorectal.<\/p>\n<p>Bien que certains effets secondaires aient \u00e9t\u00e9 signal\u00e9s, les chercheurs ont soulign\u00e9 qu&rsquo;ils correspondaient \u00e0 ceux g\u00e9n\u00e9ralement associ\u00e9s \u00e0 ce m\u00e9dicament bien connu.<\/p>\n<p>Ces r\u00e9sultats mettent en \u00e9vidence la possibilit\u00e9 de r\u00e9orienter l&rsquo;aspirine &#8211; un m\u00e9dicament abordable et largement accessible &#8211; vers le traitement du cancer colorectal, tout en soulignant l&rsquo;importance des tests g\u00e9nomiques pour identifier les personnes susceptibles de b\u00e9n\u00e9ficier de l&rsquo;aspirine, en particulier celles qui pr\u00e9sentent des alt\u00e9rations sp\u00e9cifiques de\u00a0<em>PIK3CA.<\/em><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mars 2025 Une \u00e9tude de phase 3 pr\u00e9sent\u00e9e lors du\u00a0Gastrointestinal Cancers Symposium\u00a0de 2025 a montr\u00e9 que l&rsquo;utilisation d&rsquo;aspirine pendant trois ans r\u00e9duisait de mani\u00e8re significative le risque de r\u00e9cidive chez les patients atteints de cancer colorectal pr\u00e9sentant des mutations du g\u00e8ne\u00a0PIK3CA. Qu&rsquo;est-ce que\u00a0PIK3CA? PIK3CA\u00a0est un g\u00e8ne commun\u00e9ment mut\u00e9 (modifi\u00e9) dans <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/laspirine-reduit-le-risque-de-recidive-du-cancer-colorectal-chez-les-patients-presentant-des-mutations-p13k\/\">&#8230;<\/a><\/p>\n","protected":false},"author":5,"featured_media":15972,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[42,57,98],"tags":[],"class_list":["post-15934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogue","category-essais-cliniques","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/15934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=15934"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/15934\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/15972"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=15934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=15934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=15934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}